Q32 Bio Appoints Experienced Biopharmaceutical Leader Mark Iwicki as Chairman of Board of Directors
Cambridge, Mass. (December 22nd, 2020) – Q32 Bio, a biotechnology company developing therapeutics to restore healthy immune regulation, today announced the appointment of industry leader Mark Iwicki as Chairman of their Board of Directors. Mr. Iwicki will succeed Dr. David Grayzel as Chairman. Dr. Grayzel, an Atlas Venture partner and co-founder of Q32, will continue as a Director. Read More >